Drug Trial Radar · NCT02207634
Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
Last checked: Nov 20, 2026Latest source record: Jan 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,974
Actual
Start
Sep 10, 2014
Primary completion
Nov 11, 2016
Study completion Nov 11, 2016
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.
Conditions
- Dyslipidemia
Interventions
EvolocumabBiological
Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
PlaceboDrug
Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Background Statin TherapyDrug
Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z ScoreTime frame: Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).
Locations
416 sites in 30 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Huntsville, Alabama
Research Site
Mobile, Alabama
Research Site
Glendale, Arizona
Research Site
Phoenix, Arizona
Research Site
Alhambra, California
Research Site
Banning, California
Research Site
Harbor City, California
Research Site
Laguna Hills, California
Research Site
Long Beach, California
Research Site
Long Beach, California
Research Site
Oceanside, California
Research Site
Oxnard, California
Research Site
Palm Springs, California
Research Site
Roseville, California
Research Site
Sacramento, California
Research Site
San Pedro, California
Research Site
Tarzana, California
Research Site
Thousand Oaks, California
Research Site
Aurora, Colorado
Research Site
Colorado Springs, Colorado
Research Site
Denver, Colorado
Research Site
Bridgeport, Connecticut
Research Site
Boynton Beach, Florida
Research Site
Crystal River, Florida
Research Site
Daytona Beach, Florida
Research Site
Deerfield Beach, Florida
Research Site
Fleming Island, Florida
Research Site
Hollywood, Florida
Research Site
Hollywood, Florida
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Palm Harbor, Florida
Research Site
Pembroke Pines, Florida
Research Site
Ponte Vedra, Florida
Research Site
Sarasota, Florida
Research Site
St. Petersburg, Florida
Research Site
Tampa, Florida
Research Site
West Palm Beach, Florida
Research Site
Atlanta, Georgia
Showing 40 of 416 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.